A cross-sectional observational study to establish the association between ECOG performance status and age and administration of doublet or triplet chemotherapy containing Xeloda® (capecitabine) in advanced gastric cancer patients. (2014). European Journal of Oncology and Environmental Health, 18(4), 173-180. https://mattioli1885journals.com/index.php/EJOEH/article/view/2443